Halozyme Therapeutics, Inc. (LON:0J2O)
68.77
-0.07 (-0.10%)
Dec 29, 2025, 4:58 PM BST
Halozyme Therapeutics Employees
Halozyme Therapeutics had 350 employees as of December 31, 2024. The number of employees decreased by 23 or -6.17% compared to the previous year.
Employees
350
Change (1Y)
-23
Growth (1Y)
-6.17%
Revenue / Employee
2.64M GBP
Profits / Employee
1.27M GBP
Market Cap
6.01B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 350 | -23 | -6.17% |
| Dec 31, 2023 | 373 | -20 | -5.09% |
| Dec 31, 2022 | 393 | 248 | 171.03% |
| Dec 31, 2021 | 145 | 9 | 6.62% |
| Dec 31, 2020 | 136 | 4 | 3.03% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| Convatec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| Genus | 3,190 |
| HUTCHMED (China) | 1,811 |
Halozyme Therapeutics News
- 6 days ago - Halozyme Therapeutics Stock Sees Relative Strength Rating - Investor's Business Daily
- 11 days ago - U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer - PRNewsWire
- 14 days ago - Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade) - Seeking Alpha
- 21 days ago - Jim Lang Elected to Halozyme's Board of Directors - PRNewsWire
- 23 days ago - The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar. - The Motley Fool
- 25 days ago - Halozyme (HALO) Wins Injunction Against Merck in Germany - GuruFocus
- 25 days ago - Halozyme granted injunction in Germany barring Merck's subcutaneous Keytruda - Seeking Alpha
- 25 days ago - Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case - WSJ